CancerLinQ LLC, a wholly-owned nonprofit of the American Society of Clinical Oncology (ASCO), has announced a partnership with the Oncology Nursing Society (ONS). CancerLinQ will draw on ONS's expertise and thought leadership as it continues to provide a robust quality improvement and data-sharing platform to oncology practices and cancer centers. The collaboration builds on the CancerLinQ Ambassadors Program, which the two organisations launched in early 2017.
With more than 39,000 members and expertise in developing and implementing educational resources and oncology nurse consulting programs, ONS is well positioned to enhance the value of CancerLinQ through nurse involvement in a way that ultimately benefits cancer patients. In March 2017, CancerLinQ LLC and ONS launched the CancerLinQ Ambassadors Program, which provides on-the-ground support and guidance to CancerLinQ participating practices on a regional basis. ONS is currently recruiting credentialed nurses from its membership with experience in quality improvement, informatics, and technology to serve as ambassadors and provide leadership in the field.
As an official partnering organisation of CancerLinQ, ONS leaders will participate in the CancerLinQ Oncology Leadership Council and other CancerLinQ advisory groups, further strengthening CancerLinQ's goal to engage and grow its network of strategic alliances through coalition building efforts. ONS will also have access to de-identified data from CancerLinQ Discovery for research and learning purposes.
CancerLinQ Discovery, which launched in November, will provide curated, de-identified sets of clinical data for those interested in pursuing hypothesis-driven research. The datasets will be generated from the growing CancerLinQ database, a real-world, big-data initiative focused on rapidly improving patient care.
With the addition of ONS--and other partnerships with a number of government agencies, professional medical specialty societies, advocacy groups, and life sciences organisations--the use of CancerLinQ Discovery to learn from every patient, gather data-driven insights, create new knowledge, and leverage critical input to maximise its utility and usability is well underway. The goal is to attain insights that can improve quality and efficiency of the cancer care delivery system.
The collaboration with ONS is the latest in a series of partnerships that CancerLinQ LLC has entered with thought leaders from a variety of influential organisations from across the wide spectrum of public, private, and not-for-profit sectors. To date, CancerLinQ LLC has publicly announced formal partnerships with the American Society of Radiation Oncology (ASTRO), Cancer Informatics for Cancer Centers (CI4CC), Hematology/Oncology Pharmacy Association (HOPA), and AstraZeneca, which became the founding enterprise partner with CancerLinQ Discovery in November 2016. The goal of the strategic alliances is to create a multidisciplinary, networked coalition of committed leaders for expert guidance and to accelerate the creation of new insights from the CancerLinQ platform that can improve quality, efficiency, and value for the entire cancer care continuum.
Brought to you by Scope e-Knowledge Center, a world-leading provider of Abstracting & Indexing (A&I) Services, Knowledge Modeling Services (Taxonomies, Thesauri and Ontologies), Metadata Enrichment & Entity Extraction Services.
